Testing effectiveness (Phase 2)Looking for participantsNCT06026657
What this trial is testing
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8HER2-Negative Breast Carcinoma
Margaret Gatti-Mays 42